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Abstract
The structure and composition of bacterial communities can compromise antibiotic efficacy.
For example, the secretion of β-lactamase by individual bacteria provides passive resis-
tance for all residents within a polymicrobial environment. Here, we uncover that collective
resistance can also develop via intracellular antibiotic deactivation. Real-time luminescence
measurements and single-cell analysis demonstrate that the opportunistic human pathogen
Streptococcus pneumoniae grows in medium supplemented with chloramphenicol (Cm)
when resistant bacteria expressing Cm acetyltransferase (CAT) are present. We show that
CAT processes Cm intracellularly but not extracellularly. In a mouse pneumonia model,
more susceptible pneumococci survive Cm treatment when coinfected with a CAT-express-
ing strain. Mathematical modeling predicts that stable coexistence is only possible when
antibiotic resistance comes at a fitness cost. Strikingly, CAT-expressing pneumococci in
mouse lungs were outcompeted by susceptible cells even during Cm treatment. Our results
highlight the importance of the microbial context during infectious disease as a potential
complicating factor to antibiotic therapy.
Author Summary
Antibiotic-resistant bacterial infections are on the rise and pose a serious threat to society.
The influence of genetic resistance mechanisms on antibiotic therapy is well described.
However, other factors, such as epigenetic resistance or the impact of the environment on
antibiotic therapy, are less well understood. Here, we describe and characterize a mecha-
nism of noninherited antibiotic resistance that enables the survival and outgrowth of
genetically susceptible bacteria during antibiotic therapy. We show that bacteria express-
ing the resistance factor chloramphenicol (Cm) acetyltransferase (CAT) can potently
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deactivate Cm in their immediate environment. The reduced Cm concentration then
allows for the outgrowth of genetically susceptible bacteria in the same environment.
Mathematical modeling demonstrates the presence of a parameter space in which stable
coexistence between Cm-susceptible and -resistant bacteria is possible during antibiotic
therapy, which we validated using single-cell analyses. Strikingly, mixed culture experi-
ments in which mice were infected with both Cm-susceptible and -resistant pneumococci
revealed that Cm-sensitive “freeloader” bacteria even outcompeted resistant bacteria dur-
ing antibiotic therapy. Together, we show that the microbial context during infection is a
potential complicating factor to antibiotic treatment outcomes.
Introduction
Antibiotics are indispensable for fighting bacterial infections. Yet the rapid emergence of resis-
tance during the last decades renders current drugs increasingly ineffective and poses a serious
threat to human health [1]. Drug action and bacterial resistance mechanisms are well under-
stood in population assays of isogenic cultures in vitro. However, ecological factors and cell
physiological parameters in natural environments influence the impact of antibiotics [2,3].
Streptococcus pneumoniae (pneumococcus) is an important human pathogen that resides in
complex and dynamic host environments. The bacterium primarily populates the nasophar-
ynx of healthy individuals, together with numerous commensal microbiota, and often along-
side disease-associated species, including Staphylococcus aureus, Moraxella catarrhalis, and
Haemophilus influenzae [4–6].
While an individual pneumococcal cell competes for limited resources with all other bacte-
ria present in the niche, it may also benefit from a community setting. In a collective effort,
bacteria become recalcitrant to antibiotics when forming biofilms that represent a physical
constraint for drug accessibility [7,8]. Additional population-based survival strategies involve
the phenotypic diversification of an isogenic population, either to preadapt for environmental
changes (bet-hedging) or to enable division of labor [9]. Because the impact of most antibiotics
is growth rate dependent [10–12], a bifurcation into growing and nongrowing cells increases
the drug tolerance for the latter fraction, commonly referred to as persisters [13,14]. Cell-to-
cell communication represents another way to react to antibiotic inhibition by allowing bacte-
ria to coordinate a common response; S. pneumoniae, for example, activates the developmental
process of competence whereupon it may acquire resistance [15–17]. A quorum-sensing
mechanism that compromises antibiotic effectiveness was also found in evolved Escherichia
coli cultures, in which cells of increased resistance induce drug efflux pumps in susceptible
cells via the signaling molecule indole [18].
As an alternative to reduced drug susceptibility, bacteria can also clear lethal doses of antibi-
otics from their environment. High cell densities and thus the presence of many drug target
sites may be sufficient to lower the concentration of active compound by titration of free drug
molecules [19]. Furthermore, antibiotic degradation via β-lactamase enables growth not only
of resistant cells but also of susceptible cells in their vicinity [20–22], even across species, as
demonstrated for amoxicillin-resistant H. influenzae and susceptible S. pneumoniae [23,24].
This mechanism is of direct relevance to clinical medicine and is alternatively referred to as
passive or indirect resistance (from the perspective of susceptible cells) or collective resistance
(from the perspective of mixed populations) [25].
Here, we describe another mechanism by which bacteria survive antibiotic therapy without
obtaining genetic resistance, with the example of the bacteriostatic antibiotic chloramphenicol
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(Cm) and the opportunistic human pathogen S. pneumoniae. We show that Cm-resistant
pneumococci expressing the resistance factor Cm acetyltransferase (CAT) can provide passive
resistance for Cm-susceptible pneumococci by intracellular antibiotic deactivation. CAT cova-
lently attaches an acetyl group from acetyl coenzyme A (acetyl-CoA) to Cm [26,27] and thus
prevents the drug from binding to bacterial ribosomes [28]. Intracellular CAT in resistant bac-
teria can potently detoxify an entire environment in growth culture, semisolid surfaces of
microscopy slides, or in a mouse infection model, supporting the survival and growth of genet-
ically susceptible bacteria in the presence of initially effective Cm concentrations. Our results
expand recent findings on the basis of E. coli growth cultures and indicate a potential clinical
relevance of passive Cm resistance [29,30].
Results
Antibiotic Resistance of the Pneumococcus
Resistances to all currently prescribed antibiotics have been identified in clinical isolate strains
of S. pneumoniae [31]. Genes that transfer antibiotic resistance can be classified according to
their mode of action [32]. One class keeps the cytoplasmic drug level low by preventing drug
entry or by exporting drug molecules. Another class alters the targeted enzymes by modifying
their drug binding sites or by replacing the entire functional unit. A third class alters the drug
molecules themselves. Only members of the latter group are potential candidates for establish-
ing passive resistance. In the pneumococcus, resistance genes that deactivate antibiotics
include aminoglycoside phosphor- or acetyltransferases and cat. To date, β-lactam antibiotic-
degrading enzymes have not been reported in S. pneumoniae genomes or plasmids [33].
Standard therapy of pneumococcal infections does not include aminoglycosides because of
the relatively high intrinsic resistance of S. pneumoniae to members of this antibiotic family. In
contrast, Cm, a member of the World Health Organization Model List of Essential Medicines
[34], is regularly prescribed throughout low-income countries for infections with S. pneumo-
niae and other Gram-positive pathogens due to its broad spectrum, oral availability, and excel-
lent tissue distribution, including the central nervous system. Recently, the antibiotic was also
discussed as candidate for a comeback in developed nations due to spreading resistances
against first-line agents [35–37].
To test whether passive resistance emerges from antibiotic-deactivating resistance markers
with S. pneumoniae, we used the drug-susceptible clinical isolate D39 [38]. We constructed an
antibiotic-susceptible reporter strain expressing firefly luciferase (luc) and antibiotic-resistant
strains expressing single-copy genomic integrated kanamycin 30-phosphotransferase (aphA1),
gentamicin 30-acetyltransferase (aacC1), and chloramphenicol acetyltransferase (cat). Resistant
and susceptible cells were grown at a one-to-one ratio, and optical density (both strains) and
bioluminescence (emitted by susceptible cells only) were measured (Fig 1). Expression of cat,
but not aphA1 or aacCI, conferred passive resistance to susceptible cells (as observed by
increased luminescence in mixed populations compared with assays of susceptible cells only;
S1 Fig), mirroring prior investigations of antibiotic deactivation by resistant isolates of S. pneu-
moniae [39]. Aminoglycosides permeate the bacterial cell only at low frequency [40]; high per-
meability, however, was recently shown to represent an important precondition for the
establishment of passive resistance, explaining why the phenomenon could not be observed
with aphA1 and aacCI expression [29].
Collective Resistance to Cm In Vitro
To characterize the observed Cm collective resistance in more detail, we used the Cm-suscepti-
ble strain D-PEP2K1 (from here on CmS), which constitutively expresses luc and the
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kanamycin resistance marker aphA1 [41], and the Cm-resistant strain D-PEP1-pJS5 (from
here on CmR), which expresses cat from plasmid pJS5 [42] (see Methods). Luminescence
allowed for the real-time estimation of growth (or inhibition) of the CmS population, and
kanamycin resistance allowed for the monitoring of their viable cell count by plating assays in
the presence of kanamycin. Cm represses the growth of susceptible pneumococci at a minimal
inhibitory concentration (MIC) of 2.2 μg ml−1, and during Cm exposure, luminescence from
luc expression of susceptible pneumococci was previously shown to decrease at a rate that
depends on the applied Cm concentration [12]. However, when CmS was co-inoculated with
CAT-expressing CmR, luminescence (indicative for growth or inhibition of the CmS cell frac-
tion) recovered, both for a Cm concentration slightly above the MIC (3 μg ml−1; Fig 2A) and
even for a Cm concentration of more than two times the MIC (5 μg ml−1; S2 Fig). Lumines-
cence recovery in mixed population assays (CmR + CmS) exceeded the values measured with
CmS monoculture by up to 10-fold (Fig 2A and S2 Fig), and plating assays (with kanamycin)
revealed that the difference in viable cell count was 1,000-fold greater after 8 h of cocultivation
(Fig 2B and S2 Fig). Although Cm is commonly regarded as bacteriostatic, bactericidal activity
has also been demonstrated against S. pneumoniae [43], explaining the observed decrease in
viability of CmS monoculture (Fig 2B and S2 Fig).
To confirm that CmR cells actually deactivate Cm in the growth medium, we analyzed cul-
ture supernatant (S) by high-performance liquid chromatography (HPLC) [44]. As shown in
Fig 2C, within 4 h of growth, CmR cells entirely converted an initial Cm concentration of 5 μg
ml−1, as evidenced by the disappearance of the corresponding Cm peak at wavelength 278 nm.
New peaks (at later elution times) appeared and gradually increased in HPLC profiles of S col-
lected after 1, 2, and 4 h of cultivation; these peaks were previously shown to correspond to
acetylated Cm derivates (1- and 3-acetylchloramphenicol) [44].
Fig 1. Experimental setup to determine passive resistance. Antibiotic-susceptible cells (AbS)
constitutively expressing luc are grown together with antibiotic-resistant cells (AbR, which do not express luc).
Only when the concentration of the antibiotic in the medium is reduced by enzymatic deactivation of resistant
cells will the genetically antibiotic-susceptible cells be able to grow and produce light.
doi:10.1371/journal.pbio.2000631.g001
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Fig 2. Cm deactivation during mixed population assays. (a) Plate reader assay sets in quadruplicate (average and
standard error of the mean [s.e.m.]) measuring luminescence (symbols with color outline) and cell density
(corresponding grey symbols) of S. pneumoniae CmS growing in the presence of 3 μg ml−1 Cm, in presence (+) or
absence (−) of CmR cells. (b) Development of the count of viable CmS cells (colony-forming units per ml [CFUs ml−1])
during the cultivation assay presented in a, determined via plating in the presence of kanamycin; average values of
Collective Antibiotic Resistance
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Next, we focused on whether the initial amount of CAT-expressing CmR cells was impor-
tant for the survival and growth of CmS cells during drug treatment. To test this, we inoculated
microtiter plate wells with a fixed number of CmS cells (inoculation at optical density [OD]
0.001, corresponding to ~1.5 × 106 colony-forming units per ml [CFUs ml−1]) while varying
the number of CmR cells (Fig 2D). High inoculation densities of CmR cells (OD 0.01) resulted
in a fast recovery of luminescence activity of CmS cells; however, the peak of luminescence was
lower compared to intermediate CmR inoculation densities. This difference can be explained
by cells reaching the carrying capacity of the growth medium before the pool of Cm is
completely deactivated; luciferase expression activity was previously shown to slow down
when cultures reach high cell densities (above ~OD 0.05) [41]. Relatively low CmR inoculation
densities (OD 0.0001) also limited luminescence recovery of CmS cells during cocultivation.
This finding likely reflects fewer CmR cells requiring more time to deactivate Cm, resulting in
increased time spans of CmS drug exposure. Prolonged drug exposure of susceptible pneumo-
cocci was previously shown to result in increasing lag periods after drug removal, indicating a
more severe perturbation of cell homeostasis [12]. The time span before outgrowth of CmS
cells consequently consists of both the period required for drug clearance (by CmR cells) and
the period required to reestablish intracellular conditions allowing for cell division.
Intracellular Deactivation of Cm
To test whether Cm processing by CAT is an intracellular process, or if it takes place after secre-
tion or cell lysis, we examined the potential of the S and the cytosolic content of CmR cells to
deactivate Cm (assay scheme in Fig 2F). Precultured CmR cells were diluted to OD 0.02 and
translation activity was blocked by adding 1 μg ml−1 tetracycline ([Tc]; S. pneumoniae D39
MIC: 0.26 μg ml−1) [12] for 1 h at 37˚C to prevent ongoing protein synthesis and thus CAT
expression. Next, the Tc-treated culture was split into three fractions: cell pellet (P) and S, sepa-
rated via centrifugation, and cell culture lysate (L), obtained by sonication. The P was resus-
pended in C+Y medium containing 3 μg ml−1 Cm (and 1 μg ml−1 Tc), and 3 μg ml−1 Cm was
added to the S and the L, followed by incubation at 37˚C. After 2 h, the remaining cells and cell
debris were removed by centrifugation and filtration, and the treated medium was used to test
cell growth of a Tc-resistant variant of the CmS strain. Neither the S nor the L could support
growth of CmS, whereas medium preincubated with the P did (Fig 2E). Together, these experi-
ments indicate that CAT is only active inside living cells, in which acetyl-CoA is present [26,27].
Single-Cell Observations of Collective Resistance
Because the abovementioned experiments were performed in bulk assays, we wondered
whether CAT-expressing bacteria would also efficiently deactivate Cm, and thus support the
growth of susceptible cells, in a more complex environment, such as on semi-solid surfaces. To
do so, we spotted CmR cells together with Cm-susceptible D-PEP33 cells expressing green
fluorescent protein (GFP) on a matrix of 10% polyacrylamide C+Y medium containing 3 μg
ml−1 Cm. Indeed Cm-susceptible D-PEP33 cells were able to grow and divide under these con-
ditions (S3 Fig).
duplicates are shown. (c) Culture supernatant (S) samples after 0, 1, 2, and 4 h of CmR cultivation (inoculation at optical
density OD 0.001) in the presence of 5 μg ml−1 Cm, analyzed for Cm content by high-performance liquid
chromatography (HPLC) separation and ultraviolet (UV) detection at 278 nm. (d) Luminescence and cell density profiles
of CmS cells treated with 3 μg ml−1 Cm (inoculation at OD 0.001) in dependency of the inoculum size of CmR cells. (e, f),
CmS luminescence and growth analysis (e) in Cm-supplemented medium (3 μg ml−1) that was pretreated with CmR cell
pellet (P), S, and culture lysate (L), and controls without (C−) and with Cm (C+); (f) schematic overview of the assay (see
also Methods and S1 Data).
doi:10.1371/journal.pbio.2000631.g002
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S. pneumoniae cohabitates the human nasopharynx with other bacteria, such as S. aureus
[6]. Therefore, we investigated whether CAT-expressing S. aureus could also support growth
of Cm-susceptible S. pneumoniae in environments containing Cm. As shown in Fig 3 and S1
Movie, all S. aureus cells grew and divided from the starting point of the experiment, whereas
S. pneumoniae CmS cells did not grow initially. However, after 8 h, a fraction of CmS cells grew
out to form microcolonies. Note that CmS cells spotted in the absence of S. aureus did not
grow under these conditions (S2 Movie).
Requirements for Stable Coexistence
The observation that CmS cells grow only when Cm-deactivating cells are present in their
close vicinity (Fig 3) suggests that the establishment of collective resistance requires CmS and
CmR bacteria to be present in the same niche. However, such coexistence is subject to ecologi-
cal constraints (e.g., the competitive exclusion principle) [45], particularly if susceptible and
resistant strains compete for the same limiting resource. We therefore developed an ecological
model to assess the scope for coexistence between CAT-producing bacteria and an antibiotic-
susceptible strain (S1 Text). Consistent with this objective, we employed a minimalist model-
ing strategy and disentangled the qualitative effects of different factors (antibiotic stress, rela-
tive cost of Cm degradation and density regulation by ecological resource competition) from
the interaction between CmS and CmR bacteria rather than aiming for a precise quantitative
reconstruction of the experimental conditions. In fact, in contrast to natural environments
(such as the human nasopharynx) that provide ample opportunities for coexistence because of
spatial structure and concentration gradients of multiple resources, the model considers a
worst-case scenario for coexistence: the two populations are assumed to grow in a well-mixed,
homogeneous chemostat environment and are limited by the same resource. Nonetheless, we
found that coexistence between CmR and CmS bacteria was feasible (Fig 4A and 4B), albeit
under a restricted range of conditions (Fig 4C and S4 Fig). A mathematical analysis of the
model (S1 Text) indicates that resistant and susceptible bacteria can establish a stable coexis-
tence when CAT expression has a modest fitness cost. Without such a cost, the CmR strain is
predicted to outcompete the CmS strain in the presence of antibiotics. Conversely, if the cost
of expressing resistance is too high, the CmS strain will be the superior competitor. Interest-
ingly, the model furthermore predicts parameter ranges that result in the extinction of mixed
populations during drug treatment, while CmR populations on their own could survive (S4
and S5 Figs). A second condition for coexistence demands that the CmR population has a sig-
nificant impact on the extracellular Cm concentration in its ecological niche. This requires
that the population density reached at steady state must be high, so that coexistence can be sta-
bilized by frequency-dependent selection, generated by a negative feedback loop between the
relative abundance of drug-deactivating cells and the level of antibiotic stress in the
environment.
We note that competitive exclusion acts at a local scale in structured environments, where
the presence of spatial gradients in Cm and resources may help to create refuges in which
either strain can escape competition from the other. In addition, we expect that coexistence
between resistant and susceptible bacteria would be promoted in vivo by previously evolved
ecological niche partitioning between co-occurring species.
In Vivo Collective Cm Resistance
A general prediction from our mathematical model (S1 Text) is that coexistence of CmS and
CmR in the presence of the antibiotic is precluded when the production of CAT carries no fit-
ness cost; we expect this prediction to apply likewise in more complex environments with
Collective Antibiotic Resistance
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spatial and/or temporal heterogeneity in Cm concentrations. However, in vitro, in short-term
experiments, we did not observe any obvious fitness cost for CAT expression (such as reduced
growth rates or a reduced maximum cell density; Fig 2). Nevertheless, in vivo, a fitness cost
might come into existence because resistant cells that grow rapidly might be preferentially
Fig 3. Interspecies collective resistance. Still images (overlay of phase contrast and fluorescence microscopy) of a time-
lapse experiment of S. pneumoniae CmS, cocultivated with a strain of the pneumococcal niche competitor S. aureus (strain
LAC pCM29) that expresses CAT and GFP, growing on a semi-solid surface supplemented with 3 μg ml−1 Cm. Scale bar
10 μm.
doi:10.1371/journal.pbio.2000631.g003
Fig 4. Population dynamics of bacterial communities. (a) Simulated growth trajectories for CmR and CmS populations subject to antibiotic stress and
resource competition. (b) Dynamic of intracellular Cm (yr and ys) and growth-limiting resource (z). Simulation time is scaled relative to the mean residence
time of cells in a chemostat, which is equal to the generation time at steady state. At low population densities, the CmR strain can grow, whereas CmS
cannot, due to a high concentration of Cm. However, the invasion of CmR lowers antibiotic stress, generating permissive conditions for the growth of CmS
cells. The chemostat is then rapidly colonized by both strains (shortly after t = 180) until the resource becomes limiting. From that moment onwards, total
cell density changes little, while the relative frequencies of the two strains continue to shift. Eventually, a stable equilibrium is reached, at which the cost
and benefit of CAT expression (i.e., reduced growth rate efficiency for CmR cells versus their lower intracellular Cm concentration) balance out. Inset (c),
The dark-red dot pinpoints the parameter set used in the simulation shown in a and b: r = 20.0, η = 0.9, kz = 4.0, c = 1.0, p = 50.0, hY = 0.25/Y0, kY = 2.5/Y0,
d = 30.0/Y0 and Y0 = 0.8. These parameters were selected to lie in a restricted area of parameter space (highlighted in red) where stable coexistence
between CmS and CmR cells is observed Alternative model outcomes, which were identified by a numerical bifurcation analysis (see S1 Text and S4 Fig),
include establishment of CmS only (area S), establishment of CmR only (area R), no bacterial growth (area N), and competition-induced extinction (area E,
where CmS bacteria first outcompete CmR bacteria and subsequently are cleared by the antibiotic; see S5 Fig).
doi:10.1371/journal.pbio.2000631.g004
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targeted by the host innate immune system, as previously shown for commensal and patho-
genic bacteria, including E. coli and S. aureus [46]. We tested the activity of the human antimi-
crobial peptide LL-37 in dependency of Cm treatment and found, indeed, increased killing
efficiency against CAT-expressing S. pneumoniae (S6 Fig). Furthermore, although collective
resistance could be successfully demonstrated in vitro, the phenomenon might not occur in
more complex environments in vivo, such as in an animal infection model, because of a differ-
ent flux balance between local Cm deactivation and restoration of effective drug concentra-
tions via diffusion from surrounding tissues. To examine whether a coexistence between CmS
and CmR is possible under therapy in vivo, we performed intratracheal infection of 8-wk-old
female CD-1 mice with CmS alone and the combination of CmS + CmR.
In the absence of Cm treatment, we observed no significant difference in the amount of via-
ble bacteria recovered from the lungs 24 h after infection with CmS alone versus CmS + CmR
at a one-to-one ratio (Fig 5A). When mice were given three doses of 75 mg kg−1 Cm once
every 5 h, mice infected with CmS alone demonstrated a significant drop of one log-fold versus
the untreated control. This is in contrast to mice coinfected with CmS + CmR, in which Cm
treatment did not significantly reduce the number of viable bacteria recovered from the lung
versus the untreated control (Fig 5A). In the one-to-one mixed infection, approximately equal
numbers of CmS and CmR cells were recovered in the absence of Cm treatment: 46% CmS and
54% CmR (Fig 5B). Surprisingly, with Cm treatment, 6 out of 14 animals had a dramatic
increase in the percentage of CmS cells versus CmR cells. No pneumococcal colonies recovered
could grow in both Cm- and kanamycin-containing media, excluding the possibility that hori-
zontal gene transfer of the cat gene occurred during coinfection. Together, these results show
that passive Cm resistance and the coexistence of resistant and susceptible cells also occur in
vivo, associated with a fitness cost to the CmR niche members benefiting the CmS
subpopulation.
Discussion
This work elucidates that CAT, which is commonly found as a resistance marker in the human
microbiome [47–49], can effectively protect Cm-susceptible pneumococci from the activity of
the drug within local environments occupied by CAT-expressing cells. Because of its potency,
long shelf life, and low cost, Cm remains a mainstay of broad-spectrum antibiotic therapy in
several countries in Africa, the Indian subcontinent, and China [50]. The rise of multidrug
resistance among human pathogens has also provoked interest in reevaluating Cm for certain
serious infections in developed countries [35–37]. This work points out some caveats in using
Cm to target human pathogens on mucosal surfaces because CAT-expressing commensals
might provide passive resistance.
CAT can only deactivate Cm inside living cells (Fig 2E and 2F), presumably because it
needs acetyl-CoA to acetylate and deactivate the target drug [26,27]. We show that Cm deacti-
vation and collective resistance via CAT is not limited to S. pneumoniae, because CAT-express-
ing S. aureus can also support the local growth of pneumococci in the presence of initially
effective Cm concentrations (Fig 3). Collective resistance by CAT does not only occur in vitro
but also in vivo in a mouse pneumonia model (Fig 5). Strikingly, when Cm-treated mice were
coinfected with CAT-expressing and Cm-susceptible pneumococci, the susceptible bacteria
outcompeted the resistant ones (Fig 5). We previously showed that the susceptibility of bacte-
ria towards antimicrobial peptides, produced by the host innate immune system, is markedly
diminished in the presence of bacteriostatic antibiotics; Cm-inhibited E. coli, for example, are
less efficiently cleared by the human peptide LL-37 [46]. We could demonstrate that this mech-
anism also takes place in S. pneumoniae (S6 Fig). When Cm was added to LL-37 treatment of
Collective Antibiotic Resistance
PLOS Biology | DOI:10.1371/journal.pbio.2000631 December 27, 2016 9 / 19
pneumococci, the number of CmS cells recovered was one log-fold higher compared with
CmR cells (S6 Fig). As shown before, this effect occurs because bacteriostatic antibiotics, such
as Cm, inhibit the growth of susceptible bacteria and thereby reduce the susceptibility to host
antimicrobial peptides that target bacterial division; Cm-resistant bacteria, in contrast, main-
tain fast growth in the presence of Cm and are therefore more rapidly killed by host antimicro-
bial peptides in vivo [46]. This phenomenon may therefore represent a contributing factor
underlying our findings of the mouse pneumonia model. In this framework, rapidly growing
CmR cells would suffer immune clearance, while the initially nongrowing CmS are less effi-
ciently targeted by host defense factors. Once the Cm concentration has dropped sufficiently,
CmS cells can outgrow and outcompete the diminished CmR population.
Our work with CAT and pneumococcus extends the known phenomenon of passive resis-
tance via β-lactamase expression and expands on recent findings of collective resistance of bac-
terial communities [29,30]. Intracellular antibiotic deactivation requires a high drug
permeability, and it is worth noting that this—in general desired—drug characteristic can also
represent a risk factor for the effectiveness of an antibiotic therapy. Passive resistance could
also appear with other antibiotic-degrading resistance factors in other bacteria [29] and may
even emerge for synthetic antibiotic compounds [51]. In light of numerous reports of preva-
lence of drug resistance in pathogens, successful antibiotic therapy might become increasingly
complicated with the occurrence of collective resistance. The phenomena could furthermore
give rise to multidrug resistance of bacterial communities, in which individual resistances are
expressed in different bacterial community residents [2,18,30]. Our mathematical model, how-
ever, predicts that collective resistance is only sustainable when resistance expression comes
at a (modest) fitness cost (S4 Fig), and competitive exclusion is avoided by strong ecological
feedback or alternative mechanisms (such as spatiotemporal structure or previously evolved
niche partitioning). Nevertheless, even if coexistence is limited, the prolonged survival of sus-
ceptible cells within resistant communities may already represent an issue by increasing the
Fig 5. Cross-protection in a mouse pneumonia model. (a) Eight-wk-old female CD1 mice were infected
intratracheally with CmS pneumococci or an equivalent amount of CmS + CmR pneumococci in a one-to-one
ratio. One h post infection, mice were treated with one intraperitoneal injection of Cm 75 mg kg−1 followed by two
additional doses spaced 5 h apart. Control mice received an injection of the vehicle alone. n = 14 for CmS
control; 13 for CmS Cm-treated; 13 for CmS + CmR control; and 14 for CmS + CmR Cm-treated. Data plotted as
average and s.e.m. of two independent experiments combined. Dashed line ‘inoc’ denotes the initial inoculum.
*p < 0.05; one-way ANOVA with Tukey’s multiple comparison post-test. (b) Bacterial colonies recovered from
the CmS + CmR control and CmS + CmR Cm-treated mice were individually picked and used to inoculate THY
media in 96-well plates. These 96-well plates were then used to inoculate 96-well plates with THY media
containing either 15 μg ml−1 Cm or 100 μg ml−1 kanamycin to determine whether or not the original bacterial
colony was CmS or CmR. n = 9 for CmS + CmR control and 14 for CmS + CmR Cm-treated. Data plotted as
average and s.e.m. of two independent experiments combined. *p = 0.04; Mann–Whitney U test (see S1 Data).
doi:10.1371/journal.pbio.2000631.g005
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opportunity for horizontal gene transfer during antibiotic selection pressure. Passive resistance
might consequently represent an important factor towards the development of genetic multi-
drug resistance.
Methods
Strains and Growth Conditions
S. pneumoniae CmS, a Cm-susceptible D39 derivate strain that constitutively expresses luc and
a kanamycin resistance marker was used throughout. The Tc-resistant variant of this strain
contained the Tc resistance gene tetM integrated at the bgaA locus, obtained via transforma-
tion with pPP1 [52]. luc has a reported half-life of 3 min in S. pneumoniae, and luminescence
therefore gives real-time information on the level of gene expression activity [41,53]. S. pneu-
moniae CmR, expressing CAT from plasmid pJS5, was used as standard for a Cm-resistant
strain. Initial experiments were carried out with the Cm-resistant strain D-PEP1C3 that
expresses CAT from a strong synthetic promoter. S. pneumoniae D-PEP33 expressing GFP
was used as a Cm-susceptible strain in time-lapse microscopy experiments [41]. S. aureus
experiments were performed with strain LAC pCM29 [54] that constitutively expresses CAT
and GFP.
S. pneumoniae and S. aureus cells were grown in C+Y medium (pH 6.8), supplemented
with 0.5 μg ml−1 D-luciferin for luminescence measurements, at 37˚C [55]. Pre-cultures for all
experiments were obtained by a standardized protocol, in which previously exponentially
growing cells from −80˚C stocks were diluted to OD (600 nm, path length 10 mm) 0.005 and
grown until OD 0.1 in a volume of 2 ml medium inside tubes that allow for direct in-tube OD
measurements. To determine the number of colony-forming units (CFUs), S. pneumoniae
cells were plated inside Columbia agar supplemented with 3% (v v−1) sheep blood and incu-
bated overnight at 37˚C.
Microtiter Plate Reader Assays
Costar 96-well plates (white, clear bottom) with a total assay volume of 300 μl per well were
inoculated to the designated starting OD value. Microtiter plate reader experiments were per-
formed using a TECAN infinite pro 200 plate reader (Tecan Group) by measuring every 10
min with the following protocol: 5 s shaking, OD (595 nm, path length 10 mm) measurement
with 25 flashes, luminescence measurement with an integration time of 1 s.
In mixed population assays (shown in Fig 2A), all cultures were inoculated with CmS cells
to an initial cell density of OD 0.001. CmR cells were inoculated to the same density, and con-
trol cultures without CmR cells contained equal amounts of Cm-sensitive D39 wild-type cells
to correct for unspecific effects such as drug-titration via cellular Cm binding.
HPLC Analysis
S were obtained by CmR cultivation (inoculation at OD 0.001) in the presence of 5 μg ml−1 Cm
in microtiter plates (as described above). Four wells were sampled and pooled per time point
(combined volume of 1.2 ml), centrifuged to remove cells, and filtered through a 0.2 μm filter.
HPLC analysis was carried out using an Agilent 1260 Infinity system (Agilent Technologies)
with ultraviolet (UV) detection at 278 nm (maximum absorbance of Cm) [44]. An Aeris Pep-
tide XB-C18 column (Phenomenex) with 3.6 μm particle and a size of 250 × 4.60 mm was
used. Reversed-phase chromatography was carried out at a constant flow rate of 1 ml min−1,
with the mobile phase consisting of solution A: 10 mM sodium acetate buffer (pH 6.0) contain-
ing 5% acetonitrile (v v−1) and solution B: acetonitrile 0.1% TFA, according to the following
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protocol: 100 μl sample loading, 3 min 10% B, 20 min gradient 10% to 50% B, 1 min gradient
50% to 95% B, 3 min 95% B, 1 min gradient 95% to 10% B, 6 min 10% B.
Microscopy
A Nikon Ti-E microscope equipped with a CoolsnapHQ2 camera and an Intensilight light
source was used. Time-lapse microscopy was carried out by spotting pre-cultured cells on 10%
polyacrylamide slides inside a Gene Frame (Thermo Fisher Scientific) that was sealed with the
cover glass to guarantee stable conditions during microscopy. The polyacrylamide slide was
prepared with growth medium containing 3 μg ml−1 Cm. Images of fluorescing cells were
taken with the following protocol and filter settings: 0.3 s exposure for phase contrast, 0.5 s
exposure for fluorescence at 440–490 nm excitation via a dichroic mirror of 495 nm, and an
emission filter of 500–550 nm. Temperature during microscopy was controlled by an Okolab
climate incubator, and images were taken every 10 min during 20 h at 37˚C.
Mouse Infection Model
The murine pneumonia model was performed with slight modifications as previously
described [56]. Based on pilot experiments, we estimated that the number of animals required
to observe a statistical difference between the groups would exceed the technical limit of ani-
mals that could be inoculated and treated per day. Therefore, the experiment was split into 2 d
with the original pool of animals randomized to each group at the start of the multi-day experi-
ment. Prior to statistical analysis, the data were combined. Note that all intratracheal infections
were performed in a blinded fashion with respect to Cm or vehicle treatment. Eight-wk-old
female CD1 mice (Charles River Laboratories) with an average body weight of 28 g were used.
Fresh cultures of CmS and CmR were started in 10 ml of Todd-Hewitt broth containing 2%
yeast extract (THY) and 10 ml of THY supplemented with 5 μg ml−1 Cm, respectively. Cultures
were grown at 37˚C in a 5% CO2 incubator until OD (600 nm) 0.6. Bacteria were washed twice
with PBS via centrifugation at 3,220 × g at room temperature and concentrated in PBS to yield
3.5 × 107 CFU in the inoculation volume of 40 μl. For mixed infections, an equal volume of
concentrated CmS and CmR pneumococci were combined. Mice were anesthetized with 100
mg kg−1 ketamine and 10 mg kg−1 xylazine. Once sedated, the vocal chords were visualized
using an operating otoscope (Welch Allyn), and 40 μl of bacteria was instilled into the trachea
during inspiration using a plastic gel loading pipette tip. Mice were placed on a warmed pad
for recovery. After 1 h, one intraperitoneal injection of Cm 75 mg kg−1 or vehicle controls was
given, followed by two additional doses spaced 5 h apart. Mice were sacrificed with CO2 24 h
after infection.
To enumerate total surviving bacteria in the lungs, both lung lobes were removed and
placed in a 2 ml sterile micro tube (Sarstedt) containing 1 ml of PBS and 1 mm silica beads
(Biospec). Lungs were homogenized by shaking twice at 6,000 rpm for 1 min using a MagNA
Lyser (Roche), with the specimens placed on ice as soon as they were harvested. Aliquots from
each tube were serially diluted for CFU enumeration on THY plates. To determine whether or
not a colony was CmS or CmR, individual colonies from the THY plates were picked and trans-
ferred into 100 μl of THY media in 96-well plates. The 96-well plates were incubated overnight
at 37˚C in a 5% CO2 incubator. After overnight incubation, wells were mixed, and 5 μl of
media from each well was transferred into 100 μl of THY containing 15 μg ml−1 Cm or 100 μg
ml−1 kanamycin. The 96-well plates were once again incubated overnight at 37˚C in a 5% CO2
incubator, and wells were finally assessed for the presence or absence of a bacterial P. Cm
(98% purity; Sigma) for animal injection was prepared as follows: 40 mg ml−1 of Cm was
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dissolved in 800 μl of 70% ethanol in PBS to make a 50 mg ml−1 stock solution. This stock solu-
tion was diluted in PBS to 3.75 mg ml−1 for intraperitoneal injection into mice at 75 mg kg−1.
Ethics Statement
This study was carried out in strict accordance with the recommendations in the Guide for the
Care and Use of Laboratory Animals of the National Institutes of Health. The corresponding
protocol entitled “Mouse Models of Bacterial Infection and Innate Immunity” (#S00227M)
was approved by the Institutional Animal Care and Use Committee of the University of Cali-
fornia, San Diego (Animal Welfare Assurance Number: A3033-01). All efforts were made to
minimize suffering of animals employed in this study.
Modeling
The model describes the dynamic of a coculture of CAT-expressing CmR and CmS bacterial
cells growing in the presence of Cm in a chemostat environment. The two strains, with popula-
tion densities xr and xs, respectively, compete for a growth-limiting resource, z. Cm is assumed
to inhibit growth; we separately keep track of the intracellular concentrations of Cm (ys in sus-
ceptible cells and yr in resistant cells) and its concentration in the extracellular medium ym.
The equations for the growth of the two bacterial populations and the growth-limiting































where r is the maximum growth rate of CmS cells, η is the relative growth efficiency of CmR
cells, c is the resource consumption rate, and kz and hy, respectively, are the half-saturation
and inhibitory constants of the growth function. Time, resource concentration, and cell densi-
ties have been scaled relative to the flow rate of the chemostat, the resource concentration in
the inflow medium, and the number of cells that fit in the chemostat volume, respectively, in
order to reduce the number of free parameters (see S1 Text for details).
The concentrations of Cm in the different compartments, which have been scaled relative
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The processes described by the terms on the right-hand side include inflow of Cm into the
medium, passive transport of Cm between compartments at rate p, outflow from the chemo-
stat, degradation of Cm by CAT in CmR cells (according to Michaelis–Menten kinetics with
maximum rate d and half-saturation constant ky), and concentration changes due to fluctua-
tions in the volume of the compartments. Eqs (1) and (2) were solved numerically using
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Mathematica (Wolfram) or simulation software written in C++ (used for the numerical bifur-
cation analysis, based on a Runge–Kutta integration algorithm with adaptive step-size
control).
Supporting Information
S1 Fig. Antibiotic degradation in the pneumococcus. (a–c), Plate reader assay sets in quadru-
plicate (average and s.e.m.) measuring luminescence (symbols with color outline) and cell den-
sity (corresponding grey symbols) of antibiotic-resistant (AbR), antibiotic-susceptible (AbS)
and a mixture of resistant and susceptible (AbR+AbS) S. pneumoniae cells growing in the pres-
ence of 200 μg ml−1 kanamycin (a), 20 μg ml−1 gentamycin (b), and 3 μg ml−1 chloramphenicol
(c). Assays with resistant cells (AbR) were inoculated to a density of OD 0.002, mixed popula-
tions (AbR+AbS) to a density of OD 0.001 each, and susceptible cells-only (AbS) also to a den-
sity of OD 0.001 with the addition of equal amounts of D39 wild type cells to correct for
unspecific effects such as cellular drug binding. D-PEP22 that constitutively expresses firefly
luciferase was used throughout as susceptible strain. Resistant strains expressed aphA1 (a),
aacCI (b), and cat(c). Note that in aminoglycoside-inhibited cultures (a and b) luminescence
of AbR+AbS assays decreased more rapidly compared with AbS assays. This can be explained
by reduced luciferase expression rates when cultures exceed OD 0.05; AbScultures, in contrast
to AbR+AbS cultures, do not reach OD 0.05 and consequently continue to express luciferase at
a higher rate [41] (see S1 Data).
(TIF)
S2 Fig. Chloramphenicol deactivation assay at a concentration of two times the MIC. (a),
Plate reader assay sets in quadruplicate (average and s.e.m.) measuring luminescence (symbols
with color outline) and cell density (corresponding grey symbols) of chloramphenicol-suscep-
tible S. pneumoniae D-PEP2K1 (CmS) growing in the presence of 5 μg ml−1 chloramphenicol
(Cm), in presence (+) or absence (−) of resistant D-PEP1-pJS5 (CmR) cells. (b), Development
of the count of viable CmS cells (CFUs ml−1, colony-forming units per ml) during the cultiva-
tion assay presented in a, determined via plating in the presence of kanamycin; average values
of duplicates are shown (see S1 Data).
(TIF)
S3 Fig. Single-cell analysis of pneumococcal collective resistance. (a,b), Still images (overlay
of phase contrast and fluorescence microscopy) of a time-lapse experiment of chlorampheni-
col-susceptible S. pneumoniae D-PEP33 cells that constitutively express GFP, either co-culti-
vated with the CAT-expressing S. pneumoniae D-PEP1-pJS5 (a) or in monoculture (b),
growing on a semi-solid surface supplemented with 3 μg ml−1 chloramphenicol. High inocula-
tion densities were spotted, resulting in rapid chloramphenicol deactivation in the co-cultiva-
tion assay. Note that GFP, which allows for the distinction between chloramphenicol-
susceptible and -resistant cells at the beginning of the time-lapse experiment (fluorescent ver-
sus non-fluorescent), bleaches quickly in the course of the assay; inhibited susceptible cells,
even after (partial) Cm clearance, do not express sufficient levels of GFP (counteracting photo-
bleaching) to allow for a continuous detection. Scale bar, 10 μm.
(TIF)
S4 Fig. Numerical model analysis. (a–c), Colored areas indicate qualitatively different out-
comes of competition between CmS and CmR cells in model simulations, as a function of two
key parameters: the growth rate efficiency of CmR cells (1 – η quantifies the cost of CAT
expression), and the concentration of Cm in the inflow medium (Y0; ‘antibiotic stress’). (a),
An orange line borders the region in which the CmS strain can grow from low initial density.
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This is below a critical level of antibiotic stress, or in a narrow range of η values when the resis-
tant cells are present. The CmR strain can grow from low initial density in the area bordered
by a solid blue line, but can maintain high population densities over a larger area of parameter
space (i.e., in the area bordered by a dashed blue line). Stable coexistence of both strains is
maintained in a narrow parameter region (red area). When η is close to 1, CmR is always a
superior competitor (dark blue area), in line with the analytical result that coexistence cannot
be maintained unless CAT expression is costly. When CAT expression costs are high, CmS
tends to outcompete CmR. However, this process leads to an elevation of Cm in the medium,
which may eventually cause both strains to go extinct (light blue area; here, CmR can survive
on its own, but not when CmS is also present; see S5 Fig). Alternatively, CmS can persist on its
own after driving CmR to extinction (orange area). Parameters are: r = 20.0, kz = 4.0, c = 1.0,
p = 50.0, hY = 0.25/Y0, kY = 2.5/Y0 and d = 30.0/Y0. In (b), the relative benefit of CAT degrada-
tion is larger, due to a slower diffusion of Cm across the cell membrane (p = 25.0; other param-
eters as in a). (c), This panel illustrates the effect of a change in the resource consumption rate
c which affects the equilibrium population densities (c = 2.0; other parameters as in a). In this
case, CmR and CmS reach lower equilibrium densities, weakening the effect of CmR on the
environment. As a result, the conditions for coexistence become more stringent. Throughout,
we performed multiple simulations per parameter condition to search for boundary and inte-
rior equilibria, and classified the dynamics based on the stability properties of the equilibria.
Color saturation within each area gives an indication of the total cell density at equilibrium.
(TIF)
S5 Fig. Extinction induced by competition. (a), Simulated growth trajectories for CmR and
CmS populations subject to antibiotic stress and competition for a limiting resource. Here, the
CmR strain is an inferior competitor that is driven to extinction by the invasion of CmS cells,
even though the growth conditions are not permissive for the survival of CmS on its own.
Extinction is caused by a bistability in the growth dynamic of CmR cells: a critical cell density
is required to lower the concentration of Cm below the level that permits population growth.
The initial CmR cell density in the simulation was just above this critical level (indicated by a
dotted gray line); the CmR cells are not able to invade if their initial density lies below the
threshold (shown by the dashed blue trajectory). However, after successful invasion (solid blue
trajectory), the CmR cells can still be pushed below their critical density by competition with
the CmS strain, triggering the collapse of both populations. (b), Dynamics of intracellular Cm
concentrations and resource. Parameters are: r = 20.0, η = 0.85, kz = 4.0, c = 1.0, p = 50.0, hY =
0.25, kY = 2.5 and d = 30.0.
(TIF)
S6 Fig. LL-37 activity in dependency on chloramphenicol. Killing of Cm-susceptible S. neu-
moniae D-PEP2K1 (CmS) and Cm-resistant D-PEP1C3 (CmR) by the human antimicrobial
peptide LL-37 at a concentration of 50 μg ml−1, in absence (−) or presence (+) of 5 μg ml−1
chloramphenicol (Cm); average and s.e.m. of duplicates are shown. P< 0.05; two-tailed t-test
(see S1 Data).
(TIF)
S1 Text. Derivation of the mathematical model and model analysis.
(PDF)
S1 Data. Numerical values underlying the data presented in the figures.
(XLSX)
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S1 Movie. Development of interspecies collective resistance. Time-lapse microscopy experi-
ment of S. pneumoniae D-PEP2K1 (CmS), co-cultivated with a strain of the pneumococcal
niche competitor Staphylococcus aureus that expresses CAT and GFP (strain LAC pCM29),
growing on a semi-solid surface containing 3 μg ml−1 chloramphenicol. The first still frame of
the time-lapse experiment is annotated as one hour into the cultivation start (01:00); one hour
was the time required for reaching stable conditions inside the microscopy slide that allow for
automated recording. Note that GFP expression, in the case of the Cm-resistant S. aureus LAC
pCM29, is not inhibited by the Cm treatment, and GFP is consequently continuously pro-
duced (counteracting photobleaching and dilution). The observed high fluorescence is the
result of GFP expression from a multi-copy plasmid (in contrast to the single-copy genomic
integration in S. pneumoniae D-PEP33 shown in S3 Fig).
(MP4)
S2 Movie. Chloramphenicol-treated susceptible pneumococci. Time-lapse microscopy
experiment of chloramphenicol-susceptible S. pneumoniae D-PEP2K1 (CmS) monoculture
growing on a semi-solid surface containing 3 μg ml−1 chloramphenicol.
(MP4)
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